全球骨关节炎疼痛管理治疗市场 – 行业趋势和 2029 年预测

市场分析和规模

关节痛是所有年龄段人群的常见症状，与膝盖的骨骼结构有关。关节痛是由某些损伤或慢性疾病的进展引起的。膝盖疼痛会随着年龄的增长而加剧。年轻人的疼痛与身体活动或运动导致的关节过度使用有关。老年人的疼痛是由骨关节炎和类风湿性关节炎导致的关节磨损引起的。半月板损伤、肌腱炎、假性痛风、滑囊炎、肥胖和其他因素都可能导致关节疼痛。根据疾病控制和预防中心的数据，关节炎是膝盖疼痛的主要原因，影响着美国 5440 万成年人。

Data Bridge Market Research 分析称，到 2029 年，骨关节炎疼痛管理治疗市场预计将达到 153.4 亿美元的价值，预测期内的复合年增长率为 7.25%。止痛药采用率的大幅增加和政府意识的提高是推动市场增长的关键因素。

市场定义

骨关节炎是一种关节疾病，会侵袭骨骼之间的软骨，导致关节肿胀和发红，使关节难以正常活动。肿胀、活动范围减小和手臂和腿部无法活动是常见症状，尤其是当脊柱受到骨关节炎影响时。

报告范围和市场细分

Osteoarthritic Pain Management Treatment Market Dynamics

Drivers

• The rise in the awareness by government

Increased government awareness programmes about the disease will boost market growth, as will an increase in the prevalence of osteoarthritis, an increase in the population susceptible to osteoarthritis, an increase in healthcare affordability in the US, and an increase in people's knowledge and awareness, among other factors driving the osteoarthritic pain management treatment market growth.

• The increase in the personalised medicines and collaborations from market players

The rise in personalised medicines for osteoarthritis, as well as the rise in product development collaborations, will create new opportunities for the osteoarthritic pain management treatment market during the forecast period.

Regulatory Compliance

Maintaining compliance with medical reforms and regulations raises the demand for these solutions.

• Government investments for healthcare interoperability

The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the osteoarthritic pain management treatment market.

.Restraints/Challenges

The increases in the risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, as well as the increased commercialization of alternatives, are the major factors acting as restraints, and will further challenge the osteoarthritic pain management treatment market during the forecast period.

This osteoarthritic pain management treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteoarthritic pain management treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Osteoarthritic Pain Management Treatment Market

In the best-case scenario, the COVID-19 pandemic has had a significant long-term positive impact on the osteoarthritic pain management treatment market. Initially, there was a drop in the market in early 2020 as a result of lockdowns and quarantine measures. However, as the disease spread around the world, the number of laboratories, COVID-19 testing sites, and processing facilities handling SARS-CoV-2 samples, reagents, and vaccines increased expon The COVID-19 outbreak is expected to have a minor impact on the market for osteoarthritis therapeutics. Corticosteroids are one of the drugs that have seen a decrease in use. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, there may be a reduction in immune response for a few weeks after the procedure. While the risk is extremely low, it must be considered when deciding whether or not to proceed with the procedure. It should also be noted that the WHO suggested avoiding systemic corticosteroids in one of its guidelines for the management of severe acute respiratory infection in patients with coronavirus.entially.

.Recent Development

• Voltaren was introduced in the United States by GlaxoSmithKline Plc (UK) in 2020.
• Horizon Therapeutics Plc (Ireland) expanded its presence in the United States in 2020.
• Kitov Pharma Ltd. (Israel) signed an agreement with Coeptis Pharmaceuticals in 2019, which aided in the efficient distribution and commercialization of Consensi.
• Atnahs opened a sales office in Dubai, UAE, in 2018.
• Flexion Therapeutics, Inc. (US) received FDA approval for ZILRETTA in 2017.

Global Osteoarthritic Pain Management Treatment Market Scope

The osteoarthritic pain management treatment market is segmented on the basis type, drug, diagnosis, treatment and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Hip osteoarthritis
• Spinal osteoarthritis.

On the basis of type, the osteoarthritic pain management treatment market is segmented into hip osteoarthritis and spinal osteoarthritis.

Drug                                                                               

• NSAIDs
• Corticosteroids
• Hyaluronic acid injection
• Other drugs

Based on drug, the osteoarthritic pain management treatment market is segmented into NSAIDs, corticosteroids, hyaluronic acid injection and other drugs.

Diagnosis

• Imaging
• Joint fluid analysis

Based on diagnosis, the osteoarthritic pain management treatment market is segmented into imaging and joint fluid analysis.

Treatment

• Medication
• Surgery
• therapy

Based on treatment, the osteoarthritic pain management treatment market is segmented into medication, surgery and therapy.

Distribution channel

• Hospitals
• Medical institutes

Osteoarthritic pain management treatment is also segmented on the basis of distribution channel into hospitals and medical institutes.

Osteoarthritic Pain Management Treatment Market Regional Analysis/Insights

The osteoarthritic pain management treatment market is analysed and market size insights and trends are provided by country, type, drug, diagnosis, treatment and end-users as referenced above.

The countries covered in the osteoarthritic pain management treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the osteoarthritic pain management treatment market due to changing lifestyles and rising healthcare costs. a rise in research funding availability, a large patient population, rising healthcare expenditures, a well-developed healthcare sector, and government support for R&D in this region Asia-Pacific is expected to be the fastest growing region in terms of osteoarthritic pain management treatment due to the large patient population and the presence of a large market opportunity.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

骨关节炎疼痛管理治疗市场还为您提供了每个国家/地区资本设备医疗支出增长、骨关节炎疼痛管理治疗市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对骨关节炎疼痛管理治疗市场的影响的详细市场分析。数据适用于 2010-2020 年的历史时期。

竞争格局和骨关节炎疼痛管理治疗市场份额分析

骨关节炎疼痛管理治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对骨关节炎疼痛管理治疗市场的关注有关。

骨关节炎疼痛管理治疗市场的一些主要参与者包括

• 赛诺菲（法国）
• Horizo​​n Therapeutics PLC（爱尔兰）
• 强生公司（美国）
• 葛兰素史克公司（英国），
• 拜耳公司（德国）
• 雅培（美国）
• 辉瑞公司（美国）
• 礼来公司 (美国)
• Anika Therapeutics, Inc（美国）
• 诺华公司（瑞士）
• 辉凌制药（瑞士）
• Bioventus（美国）
• Zimmer Biomet Holdings, Inc.（美国）
• Fidia Farmaceutici spa（意大利）
• Flexion Therapeutics, Inc.（美国）
• Pharmed Limited（印度）
• Virchow Biotech（印度）

SKU-26326